Expansion Milestone for Redcare Pharmacy: Czech Hub Boosts Austrian Business and Growth Prospects

Pilsen Facility Takes Over the Austrian Operations

Since early December, the new fulfillment center in the Czech Republic has been serving Austria. Previously, Austrian orders were fulfilled from the company’s Dutch headquarters in Sevenum, a setup that was more complex and costly. Shorter transport routes are expected to cut expenses and shorten delivery times.

Theresa Holler, Chief Operating Officer of Redcare Pharmacy, underscored the strategic importance: “The opening marks a crucial milestone for our service and continued growth. Customers are already benefiting from faster deliveries and greater product availability.”

Key facts at a glance:
- Capacity: Up to 15 million non-Rx packages annually
- Project duration: October 2024 through December 2025, including all regulatory approvals
- Customer satisfaction: The Austrian Net Promoter Score (NPS) has continued to improve since the transition
- Personnel: Most staff are already in place, with further hires planned

New CFO, Clear Insider Signal

The expansion aligns with notable leadership changes. In early December, Hendrik Krampe stepped into the role of Chief Financial Officer. The 20-year veteran of the e-commerce sector arrives from Amazon, where he spent eight years as Finance Director for the European marketplace business.

Insider activity over the past year signals confidence in the story. Executives have purchased shares totaling around €1.66 million, well above the current share price. Supervisory Board member Michael Köhler invested about €399,000 at roughly €101 per share, while the average purchase price stood near €111. Taken together, insiders hold roughly 14% of the company’s equity.

Should investors sell immediately? Or is it worth buying Redcare Pharmacy?

Analysts Maintain an Optimistic View

Even after a decline of more than 60% from its recent high, market experts largely advocate buying Redcare Pharmacy shares. The consensus rate stands at a “Moderate Buy” with 6 buy recommendations and 1 sell recommendation. The average price target is €151, more than double the current price level.

Among the rating spread, Deutsche Bank indicates the highest potential, at €214, while UBS appears more conservative at €82. Kepler Capital and Berenberg Bank recently reiterated their buy calls with targets of €144 and €165, respectively.

Strong Q3 as a Foundation for Growth

In the third quarter of 2025, revenue rose 25% year over year to €719 million. The German prescription-drug segment grew substantially, up 82%, driven by the broader adoption of electronic prescriptions. The adjusted EBITDA margin reached 2.4%.

For the full year, management reaffirmed guidance: revenue growth of more than 25% and an EBITDA margin between 2.0% and 2.5%.

Looking ahead, the company plans to disclose its annual results on March 4, 2026, with the annual general meeting scheduled for April. This milestone supports Redcare Pharmacy’s objective of strengthening its position as Europe’s leading online pharmacy while expanding efficiency across its European operations.